Fig. 3: Metabolic alterations in M. abscessus due to IleRS silencing: disruption of branched-chain amino acid (BCAA), pantothenate, and coenzyme A pathways.

Metabolic pathway analysis based on differentially expressed metabolites between IleRS-silenced (IleRS_KD) strains and empty vector strains (PLJR962_KD) under ATC treatment (n = 5). Representative bar graphs display normalized intensity values (mean ± SD; n = 5). Statistical significance was assessed by a two-tailed paired t-test (n = 5 pairs; thresholds: P < 0.05 (*), P < 0.01 (**), P < 0.001 (***), and P < 0.0001 (****)). Metabolites increased or decreased in response to IleRS silencing are highlighted in red and blue text, respectively. Metabolites that were undetectable or unchanged are shown in black. Colored arrows indicate pathway connectivity, with text colors matching the associated pathways. G6P glucose-6-phosphate, F6P fructose-6-phosphate, FBP fructose-1,6-bisphosphate, G3P glyceraldehyde-3-phosphate, PGA 3-phosphoglycerate, S7P sedoheptulose-7-phosphate, R5P ribose-5-phosphate, E4P D-erythrose-4-phosphate, PRPP 5-phosphoribosyl 1-pyrophosphate, PYR pyruvate, PEP phosphoenolpyruvate, KIV 2-ketoisovalerate, DHP 2-dehydropantoate, P-Pan 4′-phosphopantothenate, P-Pant pantetheine-4′-phosphate, AHB (S)-2-aceto-2-hydroxybutanoate, HMOP (R)-3-hydroxy-3-methyl-2-oxopentanoate, DMP (R)-2,3-dihydroxy-3-methylpentanoate, MOP (S)-3-methyl-2-oxopentanoate, ILE isoleucine, ALA alanine, LEU leucine, VAL valine, LYS lysine, ASP aspartate.